Jan Joseph Melenhorst

faculty photo
Research Professor of Pathology and Laboratory Medicine
Department: Pathology and Laboratory Medicine
Graduate Group Affiliations

Contact information
SPE South Tower, Rm. 9-105,
3400 Civic Center Boulevard, Blg. 421
Philadelphia, PA 19104-5156
Office: 215.573.6852
Lab: N/A
Education:
BSc (Biology, Geography, Associate Professor in Continuing Education)
Moller Institute, Netherlands, 1988.
MS (Medical Biology)
Nijmegen Katholic University, Netherlands, 1991.
PhD (Immunology)
Leiden University, Netherlands, 1998.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

As a translational immunologist my interest is in improving the potency and safety of adoptive immunogene therapy via correlative studies and product/process development. My translational interest also lies in streamlining the immunogene manufacturing process while maintaining or improving product potency.

Description of Other Expertise

Immunology of human allogeneic hematopoietic stem cell transplantation.

Description of Research Expertise

My expertise is in human T cell immunology and immunogene therapy, understanding and improving the anti-tumor efficacy of gene-engineered T cells for the treatment of cancers.

Selected Publications

Kater AP, Melenhorst JJ. : CAR-T and ibrutinib vs CLL: sequential or simultaneous? Blood 135(19): 1611-1612, May 2020.

Lundh S, Jung IY, Dimitri A, Vora A, Melenhorst JJ, Jadlowsky JK, Fraietta JA.: Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer. Clin Exp Med.; doi: 10.1007/s10238-020-00628-1. Online ahead of print. Page: Epub ahead of print, April 2020.

Frey NV, Gill S, Hexner EO, Schuster S, Nasta S, Loren A, Svoboda J, Stadtmauer E, Landsburg DJ, Mato A, Levine BL, Lacey SF, Melenhorst JJ, Veloso E, Gaymon A, Pequignot E, Shan X, Hwang WT, June CH, Porter DL.: Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia. J Clin Oncol. doi: 10.1200/JCO.19.03237. Online ahead of print. April 2020.

Stadtmauer, EA, Fraietta, JA, Davis, MM, Cohen, AD, Weber, KL, Lancaster, E, Mangan, PA, Kulikovskaya, I, Gupta, M, Chen, F, Tian, L, Gonzalez, VE, Xu, J, Jung, IY, Melenhorst, JJ, Plesa, G, Shea, J, Matlawski, T, Cervini, A, Gaymon, AL, Desjardins, S, Lamontagne, A, Salas-Mckee, J, Fesnak, A, Siegel, DL, Levine, BL, Jadlowsky, JK, Young, RM, Chew, A, Hwang, WT, Hexner, EO, Carreno, BM, Nobles, CL, Bushman, FD, Parker, KR, Qi, Y, Satpathy, AT, Chang, HY, Zhao, Y, Lacey, SF, June CH: CRISPR-engineered T cells in patients with refractory cancer. Science 367(6481): eaba7365, Feb 2020.

Whitney JE, Zhang B, Koterba N, Chen F, Bush J, Graham K, Lacey S, Melenhorst JJ, Teachey DT, Mensinger JL, Yehya N, Weiss SL.: Endothelial Dysfunction is Associated with Acute Respiratory Distress Syndrome in Children with Extrapulmonary Sepsis, Critical Care Medicine. Critical Care Medicine 48(3): 344-352, 2020.

Nobles CL, Sherrill-Mix S, Everett JK, Reddy S, Fraietta JA, Porter DL, Frey N, Gill SI, Grupp SA, Maude SL, Siegel DL, Levine BL, June CH, Lacey SL, Melenhorst JJ+, Bushman FD+ : CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. J Clin Invest 130(2): 673-685, 2020 Notes: + corresponding co-senior authors.

Lambert M, Leijonhufvud C, Segerberg F, Melenhorst JJ, Carlsten M: CRISPR/Cas9-Based Gene Engineering of Human Natural Killer Cells: Protocols for Knockout and Readouts to Evaluate Their Efficacy. Methods Mol Biol. 2121: 213-239, 2020.

Frey NV, Shaw PA, Hexner EO, Pequignot E, Gill S, Luger SM, Mangan JK, Loren AW, Perl AE, Maude SL, Grupp SA, Shah NN, Gilmore J, Lacey SF, Melenhorst JJ, Levine BL, June CH, Porter DL.: Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. J Clin Oncol. 38(5): 415-422, 2020.

Singh N, Orlando E, Xu J, Xu J, Binder Z, Collins MA, O'Rourke DM, Melenhorst JJ.: Mechanisms of resistance to CAR T cell therapies. Semin Cancer Biol. 2019 Dec 19. pii: S1044-579X(19)30398-0. doi: 10.1016/j.semcancer.2019.12.002. [Epub ahead of print] Review. Dec 2019.

Stadtmauer EA, Cohen AD, Weber K, Lacey SF, Gonzalez VE, Melenhorst JJ, Fraietta JA, Plesa G, Shea J, Matlawski T, Cervini A, Mangan P, Gaymon A, Desjardins S, Lancaster E, Salas-Mckee J, Suhoski MM, Fesnak A, O'Rourke M, Lamontagne A, Siegel DL, Young RM, Chew A, Nobles CL, Bushman FD, Chang HY, Satpathy AT, Zhao Y, Hwang WT, Hexner EO, June CH.: First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma. Blood 134(Supplement_1): 49, Nov 2019 Notes: doi: 10.1182/blood-2019-122374.

back to top
Last updated: 07/08/2020
The Trustees of the University of Pennsylvania